CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to…
# CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin stand out as growth hormone secretagogues that target different receptor pathways. Their combination represents the most examined GH peptide stack in existing research literature. Search volume data shows this pairing as the top growth hormone secretagogue research topic in 2026, with over 60,000 monthly global searches.
Native GHRH 1-44 breaks down quickly due to dipeptidyl peptidase IV and other proteases, resulting in a plasma half-life under 10 minutes. For more on half-lives, check the Half-Life Calculator /tools/peptide-half-life-plotter .
CJC-1295 No DAC, also known as Modified GRF 1-29, is a synthetic version of GHRH featuring the first 29 active amino acids. It includes amino acid changes at positions 2, 8, 15, and 27 to prevent degradation. These alterations boost its plasma half-life to about 30 minutes while keeping full binding to the GHRH receptor.
This compound attaches to the GHRH receptor on pituitary somatotroph cells, triggering Gs protein-coupled cAMP increase. Higher cAMP levels activate protein kinase A, which modifies transcription factors like CREB to promote GH gene expression and release. Researchers favor the No DAC version for studies on pulsatile GH patterns.
The DAC version binds albumin through a lysine residue, extending half-life to 6-8 days for continuous GH rise. In contrast, No DAC mimics natural sharp pulses. Most studies pairing it with ipamorelin use the No DAC form to maintain pulsatility.
Ipamorelin, a pentapeptide with sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, emerged as the first highly selective growth hormone secretagogue receptor agonist. Raun and colleagues published its discovery in 1998 after screening GHRP analogues. It differs from predecessors like GHRP-2, GHRP-6, and hexarelin by avoiding major activation of the HPA axis.
This selectivity allows strong GH stimulation without notable rises in cortisol or prolactin. Ipamorelin binds GHS-R1a, the ghrelin receptor, on somatotroph cells. It signals via Gq to raise calcium through IP3/DAG and via Gi to block adenylyl cyclase.
The calcium pathway causes quick exocytosis of stored GH granules. Explore peptide terms in the Peptide Glossary /tools/peptide-glossary .
Pairing CJC-1295 with ipamorelin leverages two pathways: GHRHR from CJC-1295 and GHS-R1a from ipamorelin. These lead to GH secretion through separate signals that merge effectively. Calcium from ipamorelin and cAMP from CJC-1295 enhance protein kinase activity for greater GH granule release than expected additively.
CJC-1295 amplifies pulse height, while ipamorelin supports natural pulsatility over constant elevation. Plan cycles with the Dosage & Cycle Planner /tools/peptide-dosage-planner .
Teichman et al. 2006 reported in a human study that CJC-1295 with DAC raised GH levels 2-10 times and kept IGF-1 elevated for 6 days after injection. IGF-1, mainly liver-produced from GH, drives anabolic, repair, and metabolic actions. No similar human data exists yet for No DAC or the ipamorelin combo as of 2026.
Evidence for CJC-1295 No DAC plus ipamorelin mostly comes from in vitro and animal models. These characterize mechanisms but lack extensive human trials. The stack draws interest for studies on tissue repair, body composition, and metabolism.
This combination appears in investigations for fat loss, healing, and metabolic models. Its dual action preserves GH pulse patterns vital for physiological effects. As of 2026, published human clinical trial data on the specific No DAC and ipamorelin pairing stays limited.
Researchers value ipamorelin's clean profile and CJC-1295's pulse mimicry. Stay updated via Latest peptide news /news .
In summary, CJC-1295 No DAC and ipamorelin offer complementary GH stimulation through distinct receptors and signals. Their synergy yields stronger pulses in preclinical work, fueling ongoing research interest. Future studies may clarify human applications further.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| CJC-1295 No DAC + Ipamorelin 10mg 5+5 /product/cjc-1295-no-dac-ipamorelin-10mg | ≥98% | 10mg | $49.00 |
| Ipamorelin 10mg /product/ipamorelin-10mg | ≥98% | 10mg | $49.00 |
| CJC-1295 DAC 5mg /product/cjc-1295-dac-5mg | ≥98% | 5mg | $49.00 |
| CJC-1295 No DAC 10mg /product/cjc-1295-no-dac-10mg | ≥98% | 10mg | $49.00 |
Browse Full Catalog → /catalog
Peptides referenced: Ipamorelin, CJC-1295, Sermorelin, GHRP-6, GHRP-2, Hexarelin, Growth Hormone, IGF-1.
Related reading: Melanotan 1: Tanning Peptide with Broad Research Potential, Abaloparatide Reduces Osteoporotic Spine Fractures by 84%, AI Revolutionizes Peptide Drug Discovery and Analysis, Cyclo-zp80r Boosts NFC Orange Juice Preservation.